0.39
price down icon4.88%   -0.02
after-market 시간 외 거래: .38 -0.01 -2.56%
loading
전일 마감가:
$0.41
열려 있는:
$0.4161
하루 거래량:
1.50M
Relative Volume:
0.08
시가총액:
$25.15M
수익:
$1.16M
순이익/손실:
$-37.28M
주가수익비율:
-0.60
EPS:
-0.65
순현금흐름:
$-33.81M
1주 성능:
-20.41%
1개월 성능:
+144.06%
6개월 성능:
-78.69%
1년 성능:
-71.11%
1일 변동 폭
Value
$0.3832
$0.4161
1주일 범위
Value
$0.3101
$0.536
52주 변동 폭
Value
$0.1406
$3.5299

Glycomimetics Inc Stock (GLYC) Company Profile

Name
명칭
Glycomimetics Inc
Name
전화
240-243-1201
Name
주소
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
직원
35
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
GLYC's Discussions on Twitter

Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-07-26 다운그레이드 TD Cowen Buy → Hold
2023-12-22 개시 CapitalOne Overweight
2021-11-12 업그레이드 Jefferies Hold → Buy
2019-11-14 개시 ROTH Capital Buy
2019-08-05 다운그레이드 Jefferies Buy → Hold
2019-08-05 다운그레이드 Piper Jaffray Overweight → Neutral
2019-08-05 다운그레이드 SunTrust Buy → Hold
2019-04-12 개시 Piper Jaffray Overweight
2018-12-18 개시 H.C. Wainwright Buy
2016-07-26 개시 SunTrust Buy
2015-03-17 재확인 Stifel Buy
모두보기

Glycomimetics Inc 주식(GLYC)의 최신 뉴스

pulisher
12:45 PM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com

12:45 PM
pulisher
11:01 AM

What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register

11:01 AM
pulisher
Nov 03, 2024

INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire

Nov 03, 2024
pulisher
Nov 01, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve

Nov 01, 2024
pulisher
Oct 31, 2024

GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle

Oct 31, 2024
pulisher
Oct 31, 2024

GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

3 Penny Stocks to Watch Now, 10/31/24 - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

GlycoMimetics To Acquire Crescent Biopharma - FinSMEs

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St

Oct 30, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 29, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com

Oct 29, 2024
pulisher
Oct 29, 2024

Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results - Benzinga

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Stock Triples To Become Top Gainer On Crescent Biopharma Merger Deal: Retail Goes Wild - Barchart

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Shares Are Soaring Tuesday: Here's Why - Benzinga

Oct 29, 2024
pulisher
Oct 29, 2024

Crescent Inks Oncology Merger With $200M In Private Funding - Law360

Oct 29, 2024
pulisher
Oct 29, 2024

TSX Composite Weight Index (TXCE) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Agrees to Acquire Crescent Biopharma - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

Crescent rolls up to Glycomimetics merger, $200M in new bread - BioWorld Online

Oct 29, 2024
pulisher
Oct 29, 2024

Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Oct 29, 2024
pulisher
Oct 29, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga

Oct 29, 2024
pulisher
Oct 29, 2024

TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program - Fierce Biotech

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics enters acquisition agreement with Crescent Biopharma - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Rockville biotech GlycoMimetics to be acquired - The Business Journals

Oct 29, 2024
pulisher
Oct 29, 2024

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders - Business Wire

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics skyrockets on buyout deal - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics to acquire Crescent Biopharma in a strategic merger - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire

Oct 29, 2024
pulisher
Oct 29, 2024

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - StockTitan

Oct 29, 2024
pulisher
Oct 27, 2024

S&P 500 Energy [Sector] (SREN) QuotePress Release - The Globe and Mail

Oct 27, 2024
pulisher
Oct 21, 2024

GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World

Oct 21, 2024
pulisher
Oct 14, 2024

Analytical Lens: Exploring GlycoMimetics Inc (GLYC)’s Financial Story Through Ratios - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

TD Cowen downgrades GlycoMimetics Inc (GLYC) rating to a Hold - Knox Daily

Oct 14, 2024
pulisher
Oct 13, 2024

Renaissance Technologies LLC Buys 685,151 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World

Oct 13, 2024
pulisher
Oct 10, 2024

10% Owner Invus Public Equities, L.P. sale 260,873 shares of GlycoMimetics Inc [GLYC] - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

GLYC Stock on the Rise: A Promising Investment - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Financial Fitness Check: Examining GlycoMimetics Inc (GLYC)’s Key Ratios - The Dwinnex

Oct 10, 2024
pulisher
Oct 09, 2024

GlycoMimetics stock plunges to 52-week low of $0.14 - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

GlycoMimetics stock plunges to 52-week low of $0.14 By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 03, 2024

Balance Sheet Insights: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 03, 2024
pulisher
Oct 03, 2024

GlycoMimetics Inc [GLYC] Records 50-Day SMA of $0.1817 - Knox Daily

Oct 03, 2024

Glycomimetics Inc (GLYC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Glycomimetics Inc 주식 (GLYC) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Invus Public Equities, L.P.
10% Owner
Aug 07 '24
Sale
0.18
61,488
11,197
6,578,438
Invus Public Equities, L.P.
10% Owner
Aug 05 '24
Sale
0.19
164,523
30,996
6,695,658
Invus Public Equities, L.P.
10% Owner
Aug 06 '24
Sale
0.18
55,732
10,188
6,639,926
Invus Public Equities, L.P.
10% Owner
Aug 02 '24
Sale
0.20
286,200
57,354
6,860,181
Invus Public Equities, L.P.
10% Owner
Aug 01 '24
Sale
0.22
63,564
13,743
7,146,381
Invus Public Equities, L.P.
10% Owner
Jul 30 '24
Sale
0.22
756,835
167,185
7,209,945
Invus Public Equities, L.P.
10% Owner
Jul 29 '24
Sale
0.24
363,949
85,637
7,966,780
Invus Public Equities, L.P.
10% Owner
Jul 26 '24
Sale
0.24
258,335
62,440
8,330,729
Rock Edwin
Chief Medical Officer
Jun 20 '24
Buy
0.25
190,000
48,108
565,403
Rock Edwin
Chief Medical Officer
Jun 21 '24
Buy
0.27
115,000
30,716
680,403
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):